Ivertal

Quick links to important sections

Ivertal

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ivertal

Property Description
Active Ingredient Ivermectin
Forms Oral tablet, topical cream, topical lotion
Pharmacological Class Anthelmintic / Anti-parasitic agent
General Purpose To eliminate parasitic infestations
Origin Semi-synthetic derivative

Ivertal is a prescription-only medicine containing the active ingredient Ivermectin, a compound designed to target and eliminate parasitic organisms. Although Ivertal is a specific trade name, its formulation relies on the globally recognized generic component Ivermectin, which is consistently relied upon in global public health programs for its focused therapeutic action.


What Type of Medicine is Ivertal? (Identity, Class, and Origin)

Ivermectin is classified as an Anthelmintic and an Anti-parasitic agent, belonging to the chemical group of macrocyclic lactones. The active ingredient is a semi-synthetic derivative that was chemically modified from the naturally occurring avermectins, substances isolated from the soil bacterium Streptomyces avermitilis. This origin is clinically recognized for generating a broad-spectrum agent effective against both internal and external parasites.

The drug is functionally designated as an endectocide, reflecting its ability to address both internal parasites, such as specific parasitic worms, and external parasites, including mites and lice. Ivertal is typically available as an oral tablet for systemic treatment, which is the most common form, or as a topical cream or topical lotion for cutaneous application, allowing for administration tailored to the infection site.


What is Ivertal’s General Purpose? (Function and General Benefit)

The general purpose of Ivertal is to control and clear infestations by selectively disrupting the parasite's nervous system. This anti-parasitic function involves high-affinity, selective binding of Ivermectin to glutamate-gated chloride ion channels found in invertebrates. The subsequent disruption results in the parasite's paralysis and death, which contributes to the management of parasitic diseases globally. This mechanism ensures that the general benefit is the effective reduction of parasitic burden within the host.

What side effects are possible with Ivertal?

Possible side effects and safety information

The safety profile of Ivertal is organized by regulatory authorities into frequency-classified categories and system-organ classes, based on clinical trial and post-marketing data. The most Common side effects listed in official documents include headache, dizziness, and gastrointestinal effects such as nausea, vomiting, diarrhea, and abdominal pain. Dermatological reactions like pruritus and rash are also frequently reported.

Adverse reactions are further grouped by the affected body system, including Nervous System Disorders (e.g., somnolence, tremor) and General Disorders (e.g., fever, fatigue). Reactions related to the drug's anti-parasitic action, known as the Mazzotti reaction (a complex of fever, joint pain, and swollen lymph nodes), typically occur and resolve within the first seven days of treatment for onchocerciasis.

Serious adverse reactions are rare but officially documented, and include conditions such as Hepatitis, Severe Cutaneous Reactions (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis), and Encephalopathy. The risk of serious neurological events is heightened in individuals co-infected with the Loa loa parasite. Regulatory labels also note that the safety and efficacy have not been established in children weighing less than 15 kilograms, and caution is advised for use in patients with pre-existing hepatic or renal impairment.

Overdose and Emergency Response

️ Overdose and When to Seek Help

Overdose of Ivertal (Ivermectin) is officially documented to result in a range of systemic manifestations and requires immediate professional medical attention.

The clinical presentation of overdose, as described in regulatory documents, frequently involves gastrointestinal effects such as nausea, vomiting, abdominal pain, and diarrhea. Further signs affect the central nervous system (CNS), including headache, dizziness, blurred vision, confusion, tremors, and loss of coordination. Cardiovascular changes may also occur, notably hypotension (low blood pressure) and tachycardia (fast heart rate).

Severe Outcomes and Emergency Action

The most severe outcomes reported include seizures, coma, and death. Consequently, the official instructions mandate that anyone suspected of overdose must seek immediate medical attention and contact a Poison Control Center. Immediate assistance (calling emergency services) is required if the person has collapsed, had a seizure, or cannot be awakened.

Official Management Strategy

The regulatory profile specifies that no specific antidote is known or available for Ivermectin overdose. Management is symptomatic and supportive, which may involve procedural measures like gastric decontamination with activated charcoal or specific treatments for hypotension and seizures. A key regulatory constraint notes the increased risk of severe toxicity when patients ingest highly concentrated veterinary products or topical formulations not intended for human systemic use.

Therapeutic Uses of Ivertal

What Ivertal Treats: Main Uses and Benefits

Ivertal is commonly used to help manage specific parasitic infestations, providing supportive relief across several domains, particularly where symptoms are caused by active parasites or mites. The medication is relevant for managing intestinal threadworm infection (strongyloidiasis) and onchocerciasis (River Blindness). The medication is also relevant in clinical settings that involve ectoparasites, such as scabies and head lice, and is relevant for the management of inflammatory lesions associated with rosacea.

The treatment is relevant for managing symptoms that create noticeable physiological strain, such as chronic gastrointestinal discomfort, severe pruritus (itching), or the ocular and dermatological manifestations of microfilariae migration. By addressing the underlying parasitic agent, the medication provides support that helps ease the overall symptom burden. It contributes to improved day-to-day comfort and may assist with preventing the development of severe long-term complications.

“The treatment is applied in conditions where symptoms relate to inflammatory or irritative states, offering symptomatic relief that helps patients cope more steadily with chronic conditions.”


Quick Fact: Relief for Severe Pruritus Ivertal is commonly used to help with the intense itching and visible skin lesions that arise from mite infestations like scabies, and assists with maintaining a sense of stability.

Eligibility and Restrictions for Use

Who can and cannot use Ivertal?

The official eligibility profile for Ivertal (Ivermectin) is strictly defined by regulatory documents, focusing on patient population, age, and specific pre-existing conditions.

Contraindicated Populations Patients with a known history of hypersensitivity or allergy to Ivermectin or any component of the specific product formulation must not use this medicine. The drug is also not recommended for patients who are acutely or seriously ill.

Age-Related Eligibility The oral tablet is generally not recommended for children weighing less than 15 kilograms (approximately 33 lbs), as safety and efficacy have not been established in this population. For older adults, no specific age-based restrictions or dosage adjustments are generally mandated, though caution is advised due to age-related organ function changes.

Condition-Specific Restrictions Use during pregnancy and lactation is generally restricted to cases where the potential benefit to the mother is determined to outweigh the potential risk. Furthermore, patients from Loa loa endemic areas require specific screening before treatment due to the documented risk of a serious neurological reaction.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns of the active ingredient, Ivermectin, as recognized by regulatory authorities. The information focuses strictly on how Ivertal may affect or be affected by other products.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance Official Interaction Statement
Warfarin (Anticoagulant) Post-marketing reports have rarely noted an increase in the International Normalized Ratio (INR) when the oral formulation is co-administered, suggesting a potential enhancement of anticoagulant activity.
High-fat Meal (Food) Administration of the oral tablet following a high-fat meal results in an approximate 2.5-fold increase in bioavailability (systemic exposure) compared to administration in the fasted state.
Alcohol (Ethanol) Regulatory summaries indicate that co-consumption of alcohol may increase the risk of experiencing certain side effects.

Interaction Constraints and Metabolism

Due to the significant food-drug interaction, the regulatory label for the oral tablet includes a constraint specifying administration on an empty stomach for the treatment of strongyloidiasis and onchocerciasis to manage systemic exposure. Regarding drug metabolism, in vitro data for the topical cream formulation show that it neither inhibits nor induces cytochrome P450 (CYP450) enzymes at therapeutic concentrations. No contraindicated combinations based solely on drug-drug interaction risk are formally documented in major regulatory labels.

Mechanism of Action

Ivertal acts by engaging Glutamate-gated Chloride Channels (GluCls), which are highly specialized ion channel proteins found exclusively in the nerve and muscle cells of susceptible parasitic organisms. This interaction is a form of direct agonism that forces the channel to open, initiating the primary mechanistic cascade. This selective targeting exploits a pathway unique to invertebrates, reflecting a structural difference between parasite and host chloride channels.

The sustained opening of the GluCls triggers an immediate and massive influx of chloride ions ( Cl^-) into the parasite's nerve and muscle cells. This influx causes the cell membranes to become hyperpolarized, resulting in a sustained electrochemical state that inhibits the firing of action potentials. This molecular event cascades into the complete failure of the parasite's neuromuscular signaling, which ultimately leads to a loss of essential functional responses.

The failure of neuromuscular signaling results in flaccid paralysis across the parasite's somatic and feeding muscles, most notably the pharyngeal pump. The loss of movement and feeding function prevents the organism from controlling its location or successfully acquiring nutrients. This functional loss—paralysis and cessation of nutrient intake—represents the final breakdown of the parasite's vital systems.

Dosage and Administration Information

How to Use Ivertal (Ivermectin Tablets) — Official Administration Guidelines

Ivertal is an oral medication that must be used strictly according to specific weight-based and scheduling instructions.


Administration Scope

Feature Official Instruction
Route of Administration The approved route is Oral (by mouth).
Dosing Schedule A single dose is calculated strictly by the patient's body weight (in kilograms). The typical dose is 200 mcg/kg for strongyloidiasis or 150 mcg/kg for onchocerciasis.
Timing in Relation to Meals Tablets must be taken on an empty stomach (e.g., at least 1 hour before or 2 hours after a meal) to optimize absorption.
Preparation Requirements Tablets should be swallowed whole with water. Note: Official instructions may permit crushing the tablet for patients who cannot swallow.
Age/Weight Rules Ivertal is not recommended for use in children weighing less than 15 kg.

Frequency and Procedural Structure

The treatment is typically a single, one-time dose. It is not a daily or multi-day regimen for initial treatment. For certain conditions (like onchocerciasis) or in immunocompromised patients, retreatment may be required. This must be administered at specific intervals, such as every 6 to 12 months, based on professional follow-up.

Official Procedural Sequence:

  1. Determine the patient's accurate body weight in kilograms.
  2. Calculate the exact number of 3 mg tablets required based on the mcg/kg dose.
  3. Take the prescribed tablets with water on an empty stomach.
  4. Complete required follow-up examinations (e.g., stool tests) to confirm the treatment outcome.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ivertal

Evidence for use in Intestinal Threadworm Infection (Strongyloidiasis)

Research for this parasitic condition was evaluated through single and repeat dose studies, primarily in Randomized Controlled Trials (RCTs) where Ivertal was evaluated in comparative trials. The primary focus of this research was studied for the rate of parasite clearance, which is determined by the absence of parasite larvae or eggs in stool samples over a defined follow-up period. Findings describe patterns observed in the studies where a single-dose regimen reported specific clearance measurements. However, evidence also highlights that some patients were observed to have larvae present in their stool at a later follow-up, sometimes months after the initial treatment. Evidence is limited regarding the most effective regimen for immunocompromised patients, who are populations of interest due to their potential for complex infection.


Evidence for use in River Blindness (Onchocerciasis)

Research examining River Blindness was evaluated in large-scale public health programs and long-term observational cohorts. These studies research examined changes in the parasitic burden in endemic communities, often over many years. Outcomes related to systemic or functional imbalance were assessed through changes in the microfilariae load in the skin. Long-term community studies reported observed patterns related to changes in the prevalence of microfilariae following sustained treatment campaigns. Research has explored that the medicine was studied in relation to the larval microfilariae but not the adult worms themselves. The long-term effects are not fully established regarding the complete interruption of transmission in all highly-endemic geographical areas.


Research Gaps and What Remains Uncertain

The comprehensive evidence highlights what is known—and what is still uncertain. Evidence quality varies across studies for conditions like scabies, where differing criteria for clearance and varied follow-up times make results hard to compare. A key research gap is the availability of long-term data for most indications, particularly for later observation over several years. Furthermore, sample sizes were modest in some exploratory trials, and the research does not determine whether an individual will respond similarly to the reported group patterns. Research is ongoing to refine optimal dosing strategies and to better understand the long-term impact on public health programs.

Frequently Asked Questions (FAQ)

Common questions about Ivertal (FAQ)


Q: Does Ivertal treat the underlying cause of the condition or primarily the symptoms?

According to official product information, Ivertal is designed to eliminate the source of the parasitic infestation. It acts by paralyzing and killing the parasitic worms, thereby addressing the underlying cause of the condition.


Q: Why does Ivertal need to be taken at a specific time of day?

The official instructions require that the drug must be taken on an empty stomach to optimize the absorption of the medicine. This requirement dictates the timing relative to meals, such as maintaining the required window (e.g., at least one hour before or two hours after a meal).


Q: Is Ivertal intended for chronic, long-term use or only short-term treatment?

Official instructions state that treatment is typically a single, one-time dose. However, for certain conditions, the regimen may involve retreatment at specific intervals, such as every 3 to 12 months, based on professional follow-up and the nature of the parasitic infection.


Q: How long does it typically take to notice the expected effects of Ivertal?

The drug’s action against the parasite begins rapidly at the molecular level. However, a patient may not immediately feel the effects, and confirmation of parasite clearance or therapeutic success typically requires follow-up, which may extend over several weeks.


Q: What is considered the general timeline for Ivertal treatment success?

Official documents describe that the timeline for treatment success varies by indication. For instance, recovery for certain infestations like common scabies is typically assessed over a timeline of approximately four weeks following the single dose.


Q: Is it common for side effects of Ivertal to lessen or go away after the first few weeks?

Official information indicates that side effects related to the death of microfilariae, such as the Mazzotti reaction, are expected to occur and generally resolve within the first seven days after treatment. The persistence of other common side effects is not specifically detailed in the same manner.


Q: Does Ivertal affect a person's ability to drive or operate heavy machinery?

Certain common side effects like dizziness and somnolence (sleepiness) have been reported in official safety documents. Official patient information contains warnings regarding performing activities that require full mental alertness due to these effects.


Q: Can Ivertal cause noticeable changes in mood or behavior?

Official documentation notes that rare, serious adverse reactions involving the central nervous system have been reported. These reactions can include changes in mental status, confusion, and other neurological effects, particularly in specific co-infected individuals.


Q: Are there any common foods or beverages that should be avoided while using Ivertal?

Ivertal must be taken on an empty stomach because taking it with a high-fat meal can significantly increase the amount of the drug absorbed. Regulatory summaries also note that alcohol consumption may increase the risk of experiencing certain side effects.


Q: Does Ivertal interact with over-the-counter pain relievers like ibuprofen or acetaminophen?

Based on available regulatory data, no known interactions have been established between Ivertal and acetaminophen. The label does not specifically mention every over-the-counter pain reliever.


Q: Is it safe to use herbal supplements or high-dose vitamins while taking Ivertal?

Official patient counseling indicates that Ivertal is generally not known to interact with common vitamins or most herbal supplements. However, regulatory authorities require healthcare providers to be informed about all supplements being used to help manage potential interactions.


Q: Can people who have pre-existing kidney problems use Ivertal?

According to official product information, caution is advised when Ivertal is used by individuals with pre-existing kidney (renal) impairment. This reflects the need for careful consideration by healthcare professionals.


Q: Is Ivertal an option for people with severe liver impairment?

Official product documentation states that caution is advised when Ivertal is used by individuals with pre-existing liver (hepatic) impairment. The use of Ivertal in these cases requires careful evaluation.


Q: Is Ivertal known to cause weight gain or weight loss?

Reports from post-marketing experience indicate that unusual weight gain or loss has been observed rarely as a side effect. This information is noted in regulatory safety documentation.


Q: How does Ivertal affect the results of routine lab tests?

Official safety documents indicate that Ivertal may cause temporary changes in certain routine laboratory tests. These changes can include shifts in blood cell counts (such as eosinophilia) and an increase in liver enzyme levels.


Q: Is Ivertal still actively being studied or researched for new uses?

Studies and official information indicate that research is ongoing to explore potential new uses for Ivertal beyond its core indications. Furthermore, continued research aims to refine optimal dosing strategies for the drug's existing, approved uses.


Q: Does Ivertal contain any common allergens like gluten, lactose, or dyes?

The official product label includes a full list of inactive ingredients used in the formulation. Patients with known allergies to substances like foods, dyes, or preservatives should check this ingredient list or consult a pharmacist to ensure the product is suitable.


Q: Is it normal to feel no immediate difference when first starting Ivertal?

It is normal for a patient not to feel an immediate difference because the drug's initial effect is directed at the parasite's sub-cellular level. The physical sensation of illness resolution may not be noticeable right away after taking the single dose.


Q: What is the difference between a brand-name Ivertal and its generic equivalent?

The brand name, Ivertal, and its generic equivalent, Ivermectin, contain the same active ingredient. Regulatory bodies require that both the brand-name and generic versions meet the exact same quality and performance standards for safety and effectiveness.


Q: Are there any known long-term effects associated with Ivertal use over many years?

Studies and official information indicate that long-term effects for many of the approved indications are not fully established. This is due to a recognized limitation in the availability of long-term patient data in regulatory research.

How should Ivertal be stored and disposed of?

The storage and disposal of Ivertal (Ivermectin) must strictly follow official regulatory requirements to ensure product stability and safety.

Official Storage Requirements

Ivertal products, including oral tablets and topical cream, must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product should be kept in the original, tightly closed container and protected from excess moisture and light. It is mandatory to keep the medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Ivertal should be disposed of through a drug take-back program when available. If a take-back program is not accessible, the medicine should be mixed with an undesirable substance, such as dirt or used coffee grounds, sealed in a bag, and then placed in the trash. The medication must not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ivertal found in:

A-Z Index: